Bacteriophage treatment for drug-resistant lung infection
Part of Infections, Lungs & breathing clinical trials.
This trial tests a treatment using bacteriophages (viruses that attack specific bacteria) to fight a tough lung infection called Mycobacterium abscessus that doesn't respond to usual antibiotics. If you have this infection, this treatment might offer a new way to clear it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a lung infection caused by Mycobacterium abscessus that is resistant to multiple drugs.
- You agree to take part in the study and follow the treatment plan.
- You are willing to provide consent for participation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is a special program for one patient with a lung infection from Mycobacterium abscessus. The trial uses a treatment with bacteriophages, which are viruses that attack specific bacteria.
This trial tests a treatment using viruses that attack bacteria to fight a chronic infection in a joint replacement. It might help people whose joint infection has not cleared up with standard antibiotics or surgery.
This trial tests a new combination of antibiotics to treat a hard-to-cure lung infection caused by Mycobacterium abscessus. It compares the new combination to the standard treatment, and people with cystic fibrosis and those without can take part.
This study tests whether a new antibiotic, Contezolid, can quickly reduce the amount of Mycobacterium abscessus in your lungs. It may be a treatment option if you have had a positive sputum test in the past 6 months.
This study looks at how well phage therapy works for people with stubborn bacterial infections, like NTM. If your doctor is already considering phage therapy as part of your care, this trial may help track your response.
This study tests a new treatment that combines regular antibiotics with a special virus that attacks bacteria (called a phage) to fight lung infections that do not respond to standard antibiotics. It aims to see if this combination is safe and might help people with cystic fibrosis who have stubborn lung infections.
Hear when a new Mycobacterium Abscessus Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.